Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.51 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20546469 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL13517728 | 0.94 | MDM2 (0.53) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL13517725 | 0.94 | MDM2 (0.53) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29613539 | 0.90 | MDM4 (0.54) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29129108 | 0.90 | MDM4 (0.54) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29129111 | 0.90 | MDM4 (0.54) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29613460 | 0.90 | MDM4 (0.54) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL29818551 | 0.89 | MDM4 (0.54) | MDM4TP53MDM2TLR2CASP3 | |
| SCHEMBL18016105 | 0.86 | MDM4 (0.45) | MDM4TP53MDM2TLR2 | |
| SCHEMBL30317196 | 0.84 | MDM4 (0.55) | MDM4TP53MDM2TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3256218-B1 | A KDM1A INHIBITOR AND ITS USE IN THERAPY | IMAGO BIOSCIENCES INC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200283397-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2020-09-10 | — | — | US | disclosed |
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981922-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3256218-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| WO-2016130952-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283397-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885MDM2 1807/4885 |
| US-11230534-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885MDM2 1807/4885 |
| US-20180312474-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885MDM2 1807/4885 |
| US-20160237043-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885MDM2 1807/4885 |
| US-20220073477-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885MDM2 1807/4885 |
| US-11773068-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | MDM4 2483/4885TP53 524/4885MDM2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.